Authors' objectives: Lymphoma is a cancer of the lymphatic system, which is part of the immune system. It contains cells called lymphocytes that fight infections. Diffuse large B-cell lymphoma is the most common type of non-Hodgkin's lymphoma. It can occur at any age but is more common in those over 65 years of age. Ibrutinib is a new drug for diffuse large B-cell lymphoma. It comes in the form of capsules that are taken by mouth and swallowed. Some studies have suggested that this drug may be helpful for people with a particular type of diffuse large B-cell lymphoma who have not yet received any chemotherapy for this disease. A study is now running and is aiming to find out how well ibrutinib works alongside chemotherapy and whether it is safe to use. If ibrutinib is licensed for use in the UK, it could be a new treatment option for diffuse large B-cell lymphoma that may improve survival.

Project Status: Completed

Year Published: 2016

URL for published report: http://www.hsric.nihr.ac.uk/topics/ibrutinib-imbruvica-with-r-chop-for-diffuse-large-b-cell-lymphoma-first-line/

English language abstract: An English language summary is available

Publication Type: Not Assigned

Country: England, United Kingdom

Organisation Name: NIHR Horizon Scanning Centre

Contact Address: The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269

Contact Name: c.packer@bham.ac.uk

Contact Email: c.packer@bham.ac.uk

Copyright: NIHR Horizon Scanning Centre (NIHR HSC)